Neola Medical AB Cash Flow Conversion Efficiency
Neola Medical AB cash flow conversion efficiency. Based on the latest financial reports, Neola Medical AB (NEOLA) has a cash flow conversion efficiency ratio of -0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.48 Million ≈ $-267.32K USD) by net assets (Skr97.59 Million ≈ $10.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neola Medical AB (2018–2025)
Cash flow conversion efficiency of Neola Medical AB from 2018 to 2025. This chart illustrates how Neola Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NEOLA stock price and chart for real-time trading data and today's change.
Neola Medical AB Cash Flow Conversion Ratio Explained
Neola Medical AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neola Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neola Medical AB ranked by their cash flow conversion efficiency. Also see Neola Medical AB market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AHT Syngas Technology NV
F:3SQ1
|
0.008x |
|
CPPGroup Plc
F:4CV1
|
-2.851x |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
0.011x |
|
NanoVibronix Inc
NASDAQ:NAOV
|
-0.046x |
|
IDOX plc
LSE:IDOX
|
0.002x |
|
One SA
WAR:FMG
|
0.074x |
|
SINTEZA S.A.
RO:STZ
|
N/A |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Neola Medical AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Neola Medical AB from 2018 to 2025. Review NEOLA free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr75.80 Million ≈ $8.16 Million |
Skr-11.95 Million ≈ $-1.29 Million |
-0.158x | -0.34% |
| 2024-12-31 | Skr68.96 Million ≈ $7.42 Million |
Skr-10.84 Million ≈ $-1.17 Million |
-0.157x | -89.83% |
| 2023-12-31 | Skr79.03 Million ≈ $8.50 Million |
Skr-6.54 Million ≈ $-704.02K |
-0.083x | +34.25% |
| 2022-12-31 | Skr67.48 Million ≈ $7.26 Million |
Skr-8.50 Million ≈ $-914.41K |
-0.126x | +26.18% |
| 2021-12-31 | Skr40.63 Million ≈ $4.37 Million |
Skr-6.93 Million ≈ $-745.89K |
-0.171x | +33.89% |
| 2020-12-31 | Skr23.55 Million ≈ $2.53 Million |
Skr-6.08 Million ≈ $-653.77K |
-0.258x | -33.84% |
| 2019-12-31 | Skr10.72 Million ≈ $1.15 Million |
Skr-2.07 Million ≈ $-222.44K |
-0.193x | -94.79% |
| 2018-12-31 | Skr13.33 Million ≈ $1.43 Million |
Skr-1.32 Million ≈ $-141.95K |
-0.099x | -- |
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume chan… Read more